JenniferGreeneWelchMD

Pediatric Hematology & Oncology • Providence, RI

Assistant Professor, Pediatrics, Brown University Program in Medicine

Join to view full profile

Dr. Welch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Welch's full profile

Already have an account?

Office
593 Eddy St
Providence, RI 02903
Phone+1 401-444-5241

Fax+1 401-444-3872

Education & Training

Brown UniversityFellowship, Pediatric Hematology/Oncology, 2005 - 2008
Brown UniversityResidency, Pediatrics, 2002 - 2005
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2002

Certifications & Licensure

RI State Medical License 2005 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Start of enrollment: 2012 Jun 01
Active, not recruiting
Phase 2
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Completed
Phase 2
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Start of enrollment: 2017 Mar 03
Active, not recruiting
Phase 3
Roles: Contact
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy Start of enrollment: 2021 Jun 11
Recruiting
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

163 citations
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001)...
Andrew E. Place, Kristen E. Stevenson, Lynda M. Vrooman, Marian H. Harris, Sarah K. Hunt
The Lancet. Oncology. 2015-12-01
26 citations
Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
Melissa A. Burns, Andrew E. Place, Kristen E. Stevenson, Alejandro Gutierrez, Suzanne J. Forrest
Pediatric Blood & Cancer. 2021-01-01
23 citations
Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma.
Jennifer J.G. Welch, Cindy L. Schwartz, Meghan A. Higman, Lu Chen, Allen Buxton
Blood Advances. 2017-04-25

Abstracts/Posters

Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort
Jennifer J.G. Welch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Suny Downstate InterviewOctober 23rd, 2020
Coronavirus Notebook: What Our Zoom Backgrounds Say About UsJuly 13th, 2020
Suny Upstate Graduate Medical EducationJanuary 18th, 2021